Tech CEO Bryan Johnson says he'll make humans immortal by 2039-he just needs to sort out 'buggy' issues like 'mistakenly causing cancer' first | Fortune
Briefly

Tech CEO Bryan Johnson says he'll make humans immortal by 2039-he just needs to sort out 'buggy' issues like 'mistakenly causing cancer' first | Fortune
"For most people, success means squeezing as much as possible into 80‑odd years: a big job with a flashy title and matching salary, a swanky apartment in the city or McMansion in the suburbs, bucket‑list trips squeezed into limited vacation days, kids if they want them-and maybe an early retirement if everything goes to plan.For Silicon Valley millionaire Bryan Johnson, that feels too small."
""The search for the fountain of youth is the oldest story ever told," Johnson wrote on X and Facebook. "For the first time in the history of life on earth, in just the past 24 months, the window has opened for a conscious being to realistically strive for this goal. It is an absolutely insane moment." The 48-year-old said that the 14-year goal is based on "new, promising therapies that can turn back the clock decades,""
"The Braintree, Kernel, and most recently, Blueprint, founder admitted that his team "currently do not know" how project 2039 immortality will be achieved. But he revealed the efforts they're going to to get there, including looking into jellyfish cells and the enzymes of lobsters, which are both linked to slow ageing. "We need to port the software to humans," Johnson added."
Bryan Johnson, a Silicon Valley millionaire, is pursuing a goal to make humans immortal by 2039. He bases the 14-year target on new therapies that may reverse biological aging and on AI-accelerated innovation. Johnson acknowledges current treatments can be 'buggy' and sometimes cause cancer, and that his team does not yet know exactly how immortality will be achieved. Research directions include organ cloning, studying jellyfish cells and lobster enzymes linked to slow ageing, and treating his own body as an experimental platform. He emphasizes porting biological 'software' to humans and aims to fix dangerous side effects before scaling therapies.
Read at Fortune
Unable to calculate read time
[
|
]